Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

[This corrects the article DOI: 10.1371/journal.pone.0175207.].

Bibliographic Details
Main Authors:	Robert J Moots, Ricardo M Xavier, Chi Chiu Mok, Mahboob U Rahman, Wen-Chan Tsai, Mustafa H Al-Maini, Karel Pavelka, Ehab Mahgoub, Sameer Kotak, Joan Korth-Bradley, Ron Pedersen, Linda Mele, Qi Shen, Bonnie Vlahos
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5459555?pdf=render

id	doaj-ae31931fea8a46669c33dfddcbc80e96
record_format	Article
spelling	doaj-ae31931fea8a46669c33dfddcbc80e962020-11-25T00:24:49ZengPublic Library of Science (PLoS)PLoS ONE1932-62032017-01-01126e017930810.1371/journal.pone.0179308Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.Robert J MootsRicardo M XavierChi Chiu MokMahboob U RahmanWen-Chan TsaiMustafa H Al-MainiKarel PavelkaEhab MahgoubSameer KotakJoan Korth-BradleyRon PedersenLinda MeleQi ShenBonnie Vlahos[This corrects the article DOI: 10.1371/journal.pone.0175207.].http://europepmc.org/articles/PMC5459555?pdf=render
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Robert J Moots Ricardo M Xavier Chi Chiu Mok Mahboob U Rahman Wen-Chan Tsai Mustafa H Al-Maini Karel Pavelka Ehab Mahgoub Sameer Kotak Joan Korth-Bradley Ron Pedersen Linda Mele Qi Shen Bonnie Vlahos
spellingShingle	Robert J Moots Ricardo M Xavier Chi Chiu Mok Mahboob U Rahman Wen-Chan Tsai Mustafa H Al-Maini Karel Pavelka Ehab Mahgoub Sameer Kotak Joan Korth-Bradley Ron Pedersen Linda Mele Qi Shen Bonnie Vlahos Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS ONE
author_facet	Robert J Moots Ricardo M Xavier Chi Chiu Mok Mahboob U Rahman Wen-Chan Tsai Mustafa H Al-Maini Karel Pavelka Ehab Mahgoub Sameer Kotak Joan Korth-Bradley Ron Pedersen Linda Mele Qi Shen Bonnie Vlahos
author_sort	Robert J Moots
title	Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
title_short	Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
title_full	Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
title_fullStr	Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
title_full_unstemmed	Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
title_sort	correction: the impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: results from a multinational, real-world clinical practice, non-interventional study.
publisher	Public Library of Science (PLoS)
series	PLoS ONE
issn	1932-6203
publishDate	2017-01-01
description	[This corrects the article DOI: 10.1371/journal.pone.0175207.].
url	http://europepmc.org/articles/PMC5459555?pdf=render
work_keys_str_mv	AT robertjmoots correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT ricardomxavier correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT chichiumok correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT mahbooburahman correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT wenchantsai correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT mustafahalmaini correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT karelpavelka correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT ehabmahgoub correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT sameerkotak correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT joankorthbradley correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT ronpedersen correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT lindamele correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT qishen correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy AT bonnievlahos correctiontheimpactofantidrugantibodiesondrugconcentrationsandclinicaloutcomesinrheumatoidarthritispatientstreatedwithadalimumabetanerceptorinfliximabresultsfromamultinationalrealworldclinicalpracticenoninterventionalstudy
_version_	1725351503191867392

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Similar Items